COVID-19 mRNA vaccine-elicited T cells recognize variants of concern and phenotypically differ depending on number of vaccine doses and prior SARS-CoV-2 infection status.

Viral evolution can lead to mutations that render specific glycosylation sites dispensable for folding and for supporting the protein's function, allowing changes in the shield, and in the immunogenic profile.

Selection acting on SARS-CoV-2 variants altering the infectivity profile depends on levels of transmission in the community, and this dependence is used to infer Alpha and Delta variants infectivity profiles.

Model-inference reconstructed SARS-CoV-2 transmission dynamics in South Africa during March 2020 to February 2022, and quantified the immune erosion potential and transmissibility of three major variants (Beta, Delta, and Omicron), highlighting their common characteristics and the need for more proactive preparedness.

A replicating RNA vaccine platform generated significant immunity against SARS-CoV2 in mice and hamsters, and can be updated to target variants of concern.

Genetic evidence in humans suggests that statins reduce cancer risk via a cholesterol-independent pathway.

A large repertoire of nanobodies that target discrete regions of SARS-CoV-2 spike shows effective neutralization against variants of concern with many pairwise combinations resistant to escape and demonstrating synergistic neutralization activities.

Flight restrictions targeted at countries where SARS-CoV-2 variant-of-concern first emerged have limited effectiveness in deterring their introduction into the Netherlands due to the strength of regional travel importation risks in Europe.

Deficiencies of several DNA damage response genes can be predicted by their association with genome-wide mutation patterns.

An experimental animal model provides further insights into the host and viral mechanisms underlying airborne transmission of SARS-CoV-2.